StockData
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$11.25−0.48 (-4.09%)

Close on Nov 17, 2026Market cap $957.45MP/E –Yield –

MoonLake Immunotherapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

MoonLake Immunotherapeutics's total debt was $0 at Dec 31, 2022. For fiscal 2022 it was $0, down 100.0% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2022Dec 31, 2022$0-100.0%
FY2021Dec 31, 2021$15.00M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022$0–
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$0–
Q4 FY2021Dec 31, 2021$15.00M–

More MoonLake Immunotherapeutics figures

See a number that looks wrong?